SCHEMBL1630713

SCHEMBL1630713

Cc1ccc(C(=C2CCCCC2)c2cccc(F)c2F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.39
CES1 P23141 2/20 0.39
BCHE P06276 1/20 0.39
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38
HPGD P15428 1/20 0.38
ESR1 P03372 2/20 0.37
PGR P06401 1/20 0.37
CHRM2 P08172 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
AR P10275 1/20 0.37
CHRM1 P11229 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A3 Q01959 1/20 0.37
ATM Q13315 1/20 0.34
LMNA P02545 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ESR2 Q92731 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1630754 0.88 OPRM1 (0.48) CES2CES1OPRM1OPRD1ESR1
SCHEMBL1629224 0.86 OPRM1 (0.49) CES2CES1OPRM1OPRD1ESR1
SCHEMBL10042117 0.83 OPRM1 (0.49) CES2CES1OPRM1OPRD1LMNA
SCHEMBL1687991 0.79 ESR1 (0.47) OPRM1OPRD1HPGDESR1PGR
SCHEMBL1629223 0.77 CES2 (0.39) CES2CES1OPRM1OPRD1ESR1
SCHEMBL402574 0.76 RAB9A (0.46) ESR1SLC6A2SLC6A3LMNAESR2
SCHEMBL1631863 0.71 AKR1C3 (0.56) CES2CES1BCHEHPGDLMNA
SCHEMBL19700438 0.71 ESR1 (0.50) HPGDESR1PGRCHRM2ADORA3
SCHEMBL400604 0.69 ESR1 (0.41) CES2CES1HPGDESR1PGR
SCHEMBL1688030 0.68 ESR1 (0.49) OPRM1OPRD1HPGDESR1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470872-B2 Compounds with activity at estrogen receptors ACADIA PHARMACEUTICALS INC. (US) 2013-06-25 US disclosed
US-20120088825-A1 COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS ACADIA PHARMACEUTICALS INC. (US) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088825-A1 COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS ESRRB, ESR2, ESRRA CES2 123/4885CES1 261/4885BCHE 807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.